Avantogen: Study shows GPI-0100 improves immune response to antigens in various vaccines

By E. Janene Geiss

Philadelphia, Nov. 8 - Avantogen announced Tuesday that its proprietary adjuvant GPI-0100, a saponin derivative, is an extremely effective, non-toxic, highly stable immune booster that demonstrably improves the immune response to antigens in a great variety of vaccines.

Avantogen officials said in a company press release that they currently are seeking new collaborations with cancer vaccine developers, along with infectious disease vaccine developers and manufacturers.

Data from the studies will be presented at the upcoming annual meeting of the International Society for Biological Therapy of Cancer, and will be published in the November/December issue of the Journal of Immunotherapy, officials said.

"The head of Avantogen's programs, Dante Marciani, is a world authority on vaccine agonist structure-activity relations, as well as GMP manufacture. Dr. Marciani has recently overseen our company's involvement in several human cancer vaccine trials, and is now broadening GPI-0100's application to infectious disease vaccines as well," Dr. Leonard Firestone, Avantogen chief executive officer, said in the release.

Sydney, Australia-based Avantogen is a biotechnology company developing a broad oncology-related product portfolio. It is developing RP101, a pancreatic cancer drug in phase II clinical studies. The company's anti-cancer vaccine Pentrys is undergoing phase IIb clinical trials in prostate cancer patients. It also markets Revisys, a medical nutritional developed to address nutritional needs of patients following cancer treatment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.